RecruitingPhase IInterventional

Deferred registration: Quotient Sciences Code: QSC303849

This clinical trial (code QSC303849) is a Phase I research study run by Quotient Sciences in the UK. Phase I trials are the first step in testing a new potential medicine in humans. They help researchers understand how safe the treatment is and how it moves through the human body. This study is looking for healthy men and women aged between 18 and 55 years old. At present, the trial has a 'deferred registration'. This means regulators have permitted the sponsor to keep specific details about the medicine confidential for a short period to protect intellectual property. Complete details will be added to the public register before or on the set expiry date. Volunteers in these studies are closely monitored by doctors and nurses, and taking part is completely voluntary.

At a glance

Status

Recruiting

Phase

Phase I

Sponsor

Neurocrine Switzerland GmbH

Enrolment target

Start

19 Aug 2026

Estimated completion

06 Feb 2027

Healthy volunteers

What is this study about?

Every new medicine must go through several stages of testing before it can be prescribed by doctors. This research study is a Phase I trial, which is the very first time a treatment is tested in people. Rather than testing the drug on people who are unwell, Phase I studies usually rely on healthy volunteers. This helps scientists see how the body absorbs, breaks down, and clears the medicine without the results being confused by other illnesses.

This trial is being conducted by Quotient Sciences, a specialist clinical research organisation. Its official reference is QSC303849. The study currently has 'deferred registration' status. Under UK and international research rules, trial sponsors can sometimes delay releasing full scientific details to the public for a limited time. This protects commercial discoveries while the early research begins. It does not mean safety standards are lowered; the study still has to meet strict ethics and health authority approvals before any volunteer takes part.

Taking part in early research helps scientists decide whether a new drug is safe enough to be tested in larger groups of patients in the future. Once the deferral period ends, the full scientific name, purpose, and detailed background of the drug will be added to public clinical trial databases for anyone to read.

Key takeaways

Phase I safety study run in the UK by Quotient Sciences.
Open to healthy men and women aged 18 to 55.
Specific drug details are temporarily deferred from the public record for commercial confidentiality.
The study still follows strict national safety and ethical approvals.
Participants receive close medical supervision and compensation for time and travel.

Who may be eligible?

This study is open to healthy adults between the ages of 18 and 55. Both men and women can apply. Because it is a Phase I study, the researchers are looking for people who do not have major ongoing medical conditions, so that any effects of the medicine can be clearly identified.

Because the full trial details are deferred, the exact health checklist has not yet been shared on the public register. However, healthy volunteer studies usually require participants to have normal blood pressure, a healthy heart, and no long-term illnesses or regular prescription medicines.

If you contact the research team, they will go through a detailed screening questionnaire to see if you meet all safety criteria. They will also check factors such as smoking, alcohol use, and whether you are using reliable contraception.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am between 18 and 55 years of age.
I consider myself to be in good general health.
I do not have major long-term illnesses or daily prescription medications.
I am willing to undergo blood tests, heart checks, and a full medical exam.
I am able to attend clinic appointments or stay overnight if required.

Answer every question to see your result.

What does participation involve?

If you register interest, you will first attend a screening visit. Medical staff will explain the study in full detail and ask you to sign an informed consent form. They will check your general health through physical examinations, blood tests, urine tests, and an electrocardiogram (ECG) to monitor your heart rhythm.

Phase I trials often involve either a short stay in a specialist clinic or several daytime visits. During this time, you will receive a dose of the study medicine. Doctors and research nurses will monitor you closely to check your vital signs, collect blood samples at set times, and ask how you are feeling.

After you finish taking the medicine, there is typically a follow-up period. This may involve returning to the clinic for a final check-up to ensure you have fully recovered and remain in good health. The trial team will confirm the exact number of days, visits, and total study duration before you agree to join.

Potential risks and benefits

Phase I trials do not provide personal health benefits because they are designed to test safety rather than treat an illness. However, participants receive a thorough health check and often receive financial compensation for their time, travel, and inconvenience. The main risk is that the medicine is new, so it may cause unexpected side effects, alongside mild discomfort from tests such as blood samples. Doctors closely monitor all volunteers to keep risks as low as possible. You are always free to leave the trial at any time without giving a reason.

Locations (1)

Quotient Sciences
Approximate
Nottingham, England

Common questions

What does 'deferred registration' mean?

It means the trial sponsor has permission from regulators to hold back certain commercial details of the medicine from public registers for a short time. Strict safety rules still apply.

Why do they need healthy people instead of patients?

Healthy volunteers allow researchers to measure the medicine's safety and side effects without interference from existing diseases or other prescription drugs.

Will I be paid for taking part?

Phase I trials with healthy volunteers usually provide payment to compensate you for your time, travel expenses, and any inconvenience.

Will I have to stay overnight in a clinic?

Many Phase I studies involve staying in a dedicated research unit for one or more nights so nurses can check your health around the clock, but the team will confirm the exact schedule.

Can I leave the study if I change my mind?

Yes. Taking part is completely voluntary. You can withdraw your consent and leave the study at any point, and your future medical care will not be affected.

How to find out more

Neurocrine Switzerland GmbH Study Doctor

Centermedinfo@neurocrine.com +359 887580697 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.